Pediatrix Medical Group (NYSE:MD) Upgraded at StockNews.com

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a report issued on Thursday.

MD has been the topic of several other research reports. Jefferies Financial Group upped their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Truist Financial dropped their price target on Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating on the stock in a research report on Monday. Mizuho lifted their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Finally, Macquarie assumed coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $18.00 target price for the company. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $16.25.

Pediatrix Medical Group Stock Up 1.0 %

Shares of NYSE:MD opened at $12.73 on Thursday. The company has a market capitalization of $1.09 billion, a PE ratio of -4.16, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $16.41. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The business has a fifty day moving average price of $14.35 and a two-hundred day moving average price of $11.54.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the company posted $0.29 earnings per share. Analysts forecast that Pediatrix Medical Group will post 1.26 earnings per share for the current year.

Insider Activity

In related news, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the sale, the executive vice president now owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently bought and sold shares of MD. Quest Partners LLC raised its position in shares of Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after buying an additional 622 shares in the last quarter. Everence Capital Management Inc. lifted its stake in Pediatrix Medical Group by 7.5% during the fourth quarter. Everence Capital Management Inc. now owns 13,840 shares of the company’s stock worth $182,000 after purchasing an additional 960 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Pediatrix Medical Group by 3.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock worth $245,000 after purchasing an additional 1,088 shares in the last quarter. Quarry LP increased its position in shares of Pediatrix Medical Group by 54.1% during the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after purchasing an additional 1,662 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Pediatrix Medical Group by 0.5% during the 2nd quarter. Bank of Montreal Can now owns 415,110 shares of the company’s stock valued at $3,196,000 after buying an additional 2,083 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.